CCR2 in combination with FOLFIRINOX for advanced pancreatic ductal adenocarcinoma is in clinical phase II (NCT01413022) (Nywening et al., 2016). The gene discussed is CCR2; the disease is pancreatic ductal adenocarcinoma.